조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2024년04월
Cancer Biomarkers Market – Global Forecast to 2029
암 바이오마커 시장 : 프로파일링 기술(오믹스, 영상), 암(폐, 유방, 백혈병, 흑색종, 대장암), 제품(기기, 소모품), 용도(진단, 연구 개발, 예후), 최종 사용자 및 지역별 – 2029년까지의 세계 예측
Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region – Global Forecast to 2029
| 페이지 수 | 339 |
| 도표 수 | 417 |
| 가격 | |
| Single User License | USD 7,150 |
| Multi User License | USD 8,500 |
| Corporate License | USD 9,650 |
| Enterprise License | USD 11.000 |
| 구성 | 영문조사보고서 |
Report Overview
The global cancer biomarkers market is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period.
세계 암 바이오마커 시장은 예측 기간 동안 연평균 성장률(CAGR) 11.3%로 성장해 2024년 245억 달러 규모에서 2029년에는 420억 달러 규모에 이를 것으로 예상됩니다.
Factors like the rapid improvements in technology propel market expansion. in the creation of cancer biomarkers and the global rise in cancer incidence. However, the main obstacles to this market’s expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.
“Omics technologies segment accounted for the highest CAGR”
The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2023. This is explained by the growing use of proteomics and genomics in medication development and discovery as well as improved cancer diagnostics.
“The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period”
The market for cancer biomarkers is divided into categories according on the kind of cancer, including non-Hodgkin’s lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, and other cancer types. In the market for cancer biomarkers in 2023, the breast cancer category had the fastest growth rate. increasing progress in technology The increasing global prevalence of cancer and the development of cancer biomarkers are two important aspects driving this segment’s growth.
“Diagnostics segment accounted for the highest share”
The market for cancer biomarkers has been divided into segments based on application, including risk assessment, prognostics, diagnostics, and research & development. 2020 had the highest CAGR in the research and development sector. This can be linked to the rise in cancer biomarker research and development as well as the growing application of cancer biomarkers in medication discovery and development.
“Diagnostic Laboratories segment accounted for the highest share”
Based on end user, the cancer biomarker market is segmented into diagnostic laboratories, Biopharmaceutical Companies & CROs, research and academic institutes and other end-users. In 2023, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. he expanding number of clinical laboratories performing cancer biomarker-based diagnostics tests worldwide and the rising prevalence of malignancies are responsible for this end-user segment’s sizeable share.
“Asia Pacific: The fastest-growing region in cancer biomarkers market”
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide are driving the growth of the cancer biomarkers market in this region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level (27%), Director-level (18%), and Others (55%)
- By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)
Lists of Companies Profiled in the Cancer Biomarkers Market Report:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific, Inc. (US)
- QIAGEN N.V. (Netherlands)
- Illumina, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Abbott Laboratories (US)
- bioMérieux SA (US)
- Becton, Dickinson and Company (US)
- Merck Millipore (US)
- Agilent Technologies (US)
- Myriad Genetics, Inc. (US)
- Sysmex Corporation (Japan)
- Hologic, Inc. (US)
- Quest Diagnostics (US)
- Centogene N.V. (Germany)
- BioGenex (India),
- Siemens Healthineers (Germany)
- Exact Sciences (US)
- R&D Systems, Inc. (US)
- BioVision, Inc. (US)
- Olink (Sweden)
- Asuragen, Inc. (US)
- Meso Scale Diagnostics, LLC (US)
- Invivoscribe, Inc. (US)
- INOVIQ Ltd. (Australia)
Research Coverage
This research report categorizes the cancer biomarker market by profiling technology, cancer type, product type, application, enduser, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the Surface disinfectant market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarker market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (High prevalence of cancer, growing use for research and diagnosis), restraints (Technical issues related to sample collection and storage), opportunities (Rising healthcare expenditure, Increasing Demand from Emerging Economies), and challenges (lack of skilled professionals) influencing the growth of the cancer biomarker market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cancer biomarker market
• Market Development: Comprehensive information about lucrative markets – the report analyses the cancer biomarker market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarker market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), among others in cancer biomarker market.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
TABLE 1 INCLUSIONS AND EXCLUSIONS OF STUDY 32
1.3 STUDY SCOPE 33
1.3.1 MARKETS COVERED 33
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION 33
FIGURE 2 REGIONAL SCOPE 34
1.3.2 YEARS CONSIDERED 34
1.4 CURRENCY 34
1.5 STAKEHOLDERS 35
1.6 SUMMARY OF CHANGES 35
1.6.1 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.2 RESEARCH APPROACH 37
FIGURE 3 CANCER BIOMARKERS MARKET: RESEARCH DESIGN METHODOLOGY 37
2.2.1 SECONDARY DATA 38
2.2.1.1 Key data from secondary sources 38
2.2.2 PRIMARY DATA 39
2.2.2.1 Primary sources 40
2.2.2.2 Key data from primary sources 40
2.2.2.3 Key industry insights 41
2.2.2.4 Breakdown of primary interviews 42
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 42
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.3 MARKET SIZE ESTIMATION 42
2.3.1 BOTTOM-UP APPROACH 43
2.3.1.1 Approach 1: Company revenue estimation approach 43
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 43
2.3.1.2 Approach 2: Presentations of companies and primary interviews 44
2.3.1.3 Growth forecast 44
2.3.1.4 CAGR projections 44
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 44
2.3.2 TOP-DOWN APPROACH 45
FIGURE 8 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH 45
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 46
FIGURE 9 DATA TRIANGULATION METHODOLOGY 46
2.5 MARKET SHARE 47
2.6 STUDY ASSUMPTIONS 47
2.7 RISK ASSESSMENT 48
2.7.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET 48
2.8 GROWTH RATE ASSUMPTIONS 48
2.9 RECESSION IMPACT ANALYSIS 48
3 EXECUTIVE SUMMARY 50
FIGURE 10 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 50
FIGURE 11 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024 VS. 2029 (USD MILLION) 51
FIGURE 12 CANCER BIOMARKERS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 52
FIGURE 13 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 52
FIGURE 14 CANCER BIOMARKERS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 53
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 54
4 PREMIUM INSIGHTS 55
4.1 CANCER BIOMARKERS MARKET OVERVIEW 55
FIGURE 16 TECHNOLOGICAL ADVANCEMENTS IN CANCER BIOMARKERS TO DRIVE MARKET 55
4.2 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2024 VS. 2029 56
FIGURE 17 OMICS TECHNOLOGIES TO DOMINATE MARKET DURING FORECAST PERIOD 56
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2024 VS. 2029 56
FIGURE 18 LUNG CANCER SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2029 56
4.4 CANCER BIOMARKERS MARKET SHARE, BY PRODUCT, 2024 VS. 2029 57
FIGURE 19 INSTRUMENTS SEGMENT TO DOMINATE CANCER BIOMARKERS MARKET IN 2024 57
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2024 VS. 2029 57
FIGURE 20 DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2029 57
4.6 CANCER BIOMARKERS MARKET SHARE, BY END USER, 2024 VS. 2029 58
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58
4.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 23 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
5.2.1 DRIVERS 60
5.2.1.1 Technological advancements in cancer biomarkers 60
5.2.1.2 Increasing incidence of cancer 60
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 61
TABLE 3 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015–2035 61
5.2.1.3 Rising use of cancer biomarkers in drug discovery & development 61
5.2.1.4 Increasing R&D on cancer biomarkers 62
5.2.2 RESTRAINTS 63
5.2.2.1 Technical issues related to sample collection and storage 63
5.2.2.2 High capital investments and extensive timelines for development of cancer biomarkers 63
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS 63
5.2.2.3 Unfavorable regulatory and reimbursement scenarios 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Personalized medicine 64
FIGURE 24 WORKFLOW FOR PERSONALIZED TREATMENT 65
FIGURE 25 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS 65
5.2.3.2 Growing applications of companion diagnostics 66
TABLE 5 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS 66
5.2.3.3 Emerging economies 66
5.2.4 CHALLENGES 67
5.2.4.1 Challenges associated with cancer biomarker validation 67
5.2.4.2 Shortage of skilled professionals 67
5.3 PRICING ANALYSIS 68
5.3.1 PRICING MODEL ANALYSIS 68
TABLE 6 INDICATIVE PRICING FOR CANCER BIOMARKER PRODUCTS (2023) 68
TABLE 7 AVERAGE SELLING PRICE OF CANCER BIOMARKER PRODUCTS, BY REGION 69
5.4 PATENT ANALYSIS 70
5.4.1 PATENT ANALYSIS OF CANCER BIOMARKERS MARKET 70
FIGURE 26 PATENT ANALYSIS FOR CANCER BIOMARKERS (JANUARY 2014–DECEMBER 2023) 70
5.5 VALUE CHAIN ANALYSIS 71
FIGURE 27 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE 71
5.6 SUPPLY CHAIN ANALYSIS 72
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 72
5.7 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET 73
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 73
5.7.1 ROLE IN ECOSYSTEM 73
5.8 PORTER’S FIVE FORCES ANALYSIS 74
TABLE 8 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 74
5.8.1 THREAT OF NEW ENTRANTS 74
5.8.2 THREAT OF SUBSTITUTES 74
5.8.3 BARGAINING POWER OF BUYERS 74
5.8.4 BARGAINING POWER OF SUPPLIERS 74
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.9 REGULATORY ANALYSIS 75
5.9.1 INTRODUCTION 75
5.9.2 CANCER BIOMARKERS QUALIFICATION IN US 75
5.9.3 CANCER BIOMARKERS QUALIFICATION IN EU 75
FIGURE 30 CANCER BIOMARKERS MARKET: EMA QUALIFICATION PROCEDURE 76
5.9.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN EU AND US 76
5.9.5 EMA APPROVALS 76
5.9.6 FDA APPROVALS 77
5.10 TRADE ANALYSIS 77
5.11 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 77
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 77
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 78
5.12 TECHNOLOGY ANALYSIS 78
5.13 KEY TECHNOLOGIES 79
5.13.1 POLYMERASE CHAIN REACTION 79
5.13.2 NEXT-GENERATION SEQUENCING 79
5.14 COMPLEMENTARY TECHNOLOGIES 80
5.14.1 IN SITU HYBRIDIZATION 80
5.15 ADJACENT TECHNOLOGIES 80
5.15.1 IMMUNOHISTOCHEMISTRY 80
5.16 KEY CONFERENCES & EVENTS IN 2024–2025 80
TABLE 11 CANCER BIOMARKERS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 80
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 82
5.17.1 REVENUE SHIFT & REVENUE POCKETS FOR CANCER BIOMARKERS MARKET 82
FIGURE 31 REVENUE SHIFT FOR CANCER BIOMARKERS MARKET 82
5.18 KEY STAKEHOLDERS & BUYING CRITERIA 83
5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS 83
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS 83
5.18.2 BUYING CRITERIA 83
FIGURE 33 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS 83
TABLE 13 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS 84
5.19 CASE STUDY ANALYSIS 84
5.19.1 CASE STUDY: CASE OF OVARIAN CANCER TO ILLUSTRATE BEST PRACTICE IN MACHINE LEARNING AND SHAPLEY ANALYSIS 84
5.20 INVESTMENT & FUNDING SCENARIO 85
TABLE 14 US: CANCER BIOMARKERS FUNDING BY VARIOUS INSTITUTES/CENTERS, 2021–2024 85
6 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 86
6.1 INTRODUCTION 87
TABLE 15 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 87
6.2 OMICS TECHNOLOGIES 87
TABLE 16 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 88
TABLE 17 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 88
6.2.1 PROTEOMICS 88
TABLE 18 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 89
TABLE 19 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION) 89
6.2.1.1 Immunoassays 90
6.2.1.1.1 Facilitate diagnosis of cancer at early stage 90
TABLE 20 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 91
6.2.1.2 Mass spectrometry 91
6.2.1.2.1 High specificity of mass spectroscopy to drive adoption 91
TABLE 21 MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION) 92
6.2.1.3 2D gel electrophoresis 92
6.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment 92
TABLE 22 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2022–2029 (USD MILLION) 93
6.2.1.4 Protein microarrays 93
6.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth 93
TABLE 23 PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 94
6.2.1.5 Other proteomic technologies 94
TABLE 24 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION) 95
6.2.2 GENOMICS 95
TABLE 25 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 96
TABLE 26 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION) 96
6.2.2.1 Next-generation sequencing 97
6.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth 97
TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION) 97
6.2.2.2 Polymerase chain reaction 98
6.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market 98
TABLE 28 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION) 98
6.2.2.3 In situ hybridization 99
6.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials 99
TABLE 29 IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION) 99
6.2.3 OTHER OMICS TECHNOLOGIES 100
TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 100
6.3 IMAGING TECHNOLOGIES 101
TABLE 31 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 101
TABLE 32 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 102
6.3.1 ULTRASOUND IMAGING 102
6.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth 102
TABLE 33 ULTRASOUND IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION) 103
6.3.2 COMPUTED TOMOGRAPHY 103
6.3.2.1 Technological advancements to drive adoption 103
TABLE 34 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION) 104
6.3.3 MAGNETIC RESONANCE IMAGING 104
6.3.3.1 Growing preference for open MRIs to support market growth 104
TABLE 35 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION) 105
6.3.4 POSITRON EMISSION TOMOGRAPHY 105
6.3.4.1 Development of lab-on-chip-based multiplex assays to propel market 105
TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION) 106
6.3.5 MAMMOGRAPHY 106
6.3.5.1 Advanced technologies like 3D mammography to support market growth 106
TABLE 37 MAMMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION) 107
7 CANCER BIOMARKERS MARKET, BY CANCER TYPE 108
7.1 INTRODUCTION 109
TABLE 38 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 109
TABLE 39 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040 109
7.2 BREAST CANCER 110
7.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET 110
TABLE 40 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040 110
TABLE 41 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION) 111
7.3 LUNG CANCER 111
7.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH 111
TABLE 42 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040 112
TABLE 43 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION) 112
7.4 COLORECTAL CANCER 112
7.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET 112
TABLE 44 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040 113
TABLE 45 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION) 113
7.5 PROSTATE CANCER 113
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET 113
TABLE 46 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2029 (USD MILLION) 114
7.6 MELANOMA 114
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET 114
TABLE 47 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040 115
TABLE 48 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION, 2022–2029 (USD MILLION) 115
7.7 LEUKEMIA 116
7.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET 116
TABLE 49 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION, 2022–2029 (USD MILLION) 116
7.8 THYROID CANCER 117
7.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH 117
TABLE 50 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION, 2022–2029 (USD MILLION) 117
7.9 BLADDER CANCER 118
7.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET 118
TABLE 51 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION, 2022–2029 (USD MILLION) 118
7.10 NON-HODGKIN’S LYMPHOMA 119
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET 119
TABLE 52 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2022–2029 (USD MILLION) 119
7.11 KIDNEY CANCER 120
7.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET 120
TABLE 53 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION) 120
7.12 OTHER CANCERS 121
TABLE 54 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION) 121
8 CANCER BIOMARKERS MARKET, BY PRODUCT 122
8.1 INTRODUCTION 123
TABLE 55 CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 123
8.2 INSTRUMENTS 123
TABLE 56 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 123
TABLE 57 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 124
8.2.1 IMAGING INSTRUMENTS 124
8.2.1.1 Technological advancements in imaging instruments to drive growth 124
TABLE 58 IMAGING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 125
8.2.2 PATHOLOGY-BASED INSTRUMENTS 125
8.2.2.1 Rising demand for cancer diagnosis to drive market 125
TABLE 59 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 125
8.2.3 BIOPSY INSTRUMENTS 126
8.2.3.1 Increasing prevalence of cancer to drive growth 126
TABLE 60 BIOPSY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 126
8.3 CONSUMABLES 126
TABLE 61 CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 126
TABLE 62 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 127
8.3.1 ANTIBODIES 127
8.3.1.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market 127
TABLE 63 ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION) 128
8.3.2 KITS & REAGENTS 128
8.3.2.1 Ease of use to support adoption 128
TABLE 64 KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 128
8.3.3 PROBES 129
8.3.3.1 Need for probes in assay tests for cancer detection to support market growth 129
TABLE 65 PROBES MARKET, BY REGION, 2022–2029 (USD MILLION) 129
8.4 BIOINFORMATICS SOFTWARE 129
8.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET 129
TABLE 66 CANCER BIOMARKER BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION) 130
9 CANCER BIOMARKERS MARKET, BY APPLICATION 131
9.1 INTRODUCTION 132
TABLE 67 CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 132
9.2 DIAGNOSTICS 132
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET 132
TABLE 68 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 133
9.3 RESEARCH & DEVELOPMENT 133
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 133
TABLE 69 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 134
9.4 PROGNOSTICS 134
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH 134
TABLE 70 CANCER BIOMARKERS MARKET FOR PROGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 135
9.5 RISK ASSESSMENT 135
9.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS 135
TABLE 71 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 136
9.6 OTHER APPLICATIONS 136
TABLE 72 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 137
10 CANCER BIOMARKERS MARKET, BY END USER 138
10.1 INTRODUCTION 139
TABLE 73 CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 139
10.2 DIAGNOSTIC LABORATORIES 139
10.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH 139
TABLE 74 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 140
10.3 BIOPHARMACEUTICAL COMPANIES AND CROS 140
10.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET 140
TABLE 75 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2022–2029 (USD MILLION) 141
10.4 RESEARCH AND ACADEMIC INSTITUTES 142
10.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET 142
TABLE 76 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 143
10.5 OTHER END USERS 143
TABLE 77 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 144
11 CANCER BIOMARKERS MARKET, BY REGION 145
11.1 INTRODUCTION 146
TABLE 78 CANCER BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 146
11.2 NORTH AMERICA 147
TABLE 79 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022 147
FIGURE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT 148
TABLE 80 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 81 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 149
TABLE 82 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 83 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 84 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 85 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 86 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 151
TABLE 87 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 152
TABLE 88 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 152
TABLE 89 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 152
TABLE 90 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 153
TABLE 91 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 153
11.2.1 NORTH AMERICA: RECESSION IMPACT 153
11.2.2 US 154
11.2.2.1 Increasing use of cancer biomarkers for cancer treatment to drive market 154
TABLE 92 KEY GROWTH STRATEGIES BY LEADING PLAYERS FOR DEVELOPMENT OF CANCER BIOMARKERS 154
TABLE 93 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 155
TABLE 94 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 155
TABLE 95 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 96 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 97 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 98 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 99 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 157
TABLE 100 US: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 158
TABLE 101 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 158
TABLE 102 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 158
TABLE 103 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 159
TABLE 104 US: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 159
11.2.3 CANADA 159
11.2.3.1 Increasing government initiatives for discovery and development of cancer biomarkers to drive growth 159
TABLE 105 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 160
TABLE 106 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 161
TABLE 107 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 108 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 109 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 110 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 111 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 163
TABLE 112 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 163
TABLE 113 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 114 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 115 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 164
TABLE 116 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 165
11.3 EUROPE 165
TABLE 117 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 118 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 166
TABLE 119 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 120 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 121 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 122 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 123 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 168
TABLE 124 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 169
TABLE 125 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 126 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 127 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 170
TABLE 128 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 170
11.3.1 EUROPE: RECESSION IMPACT 170
11.3.2 GERMANY 171
11.3.2.1 Favorable government health policies to drive market 171
TABLE 129 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 171
TABLE 130 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 131 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 132 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 133 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 134 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 173
TABLE 135 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 174
TABLE 136 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 137 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 138 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 175
TABLE 139 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 175
11.3.3 UK 176
11.3.3.1 Availability of government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 176
TABLE 140 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 176
TABLE 141 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 142 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 143 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 144 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 145 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 178
TABLE 146 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 179
TABLE 147 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 148 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 149 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 180
TABLE 150 UK: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 180
11.3.4 FRANCE 180
11.3.4.1 Increasing government investments in genomics & proteomics research to drive market 180
TABLE 151 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 181
TABLE 152 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 153 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 154 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 155 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 156 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 183
TABLE 157 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 184
TABLE 158 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 159 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 160 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 185
TABLE 161 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 185
11.3.5 ITALY 185
11.3.5.1 Growing geriatric population to support market growth 185
TABLE 162 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 186
TABLE 163 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 164 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 165 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 166 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 167 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 188
TABLE 168 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 189
TABLE 169 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 170 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 171 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 190
TABLE 172 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 190
11.3.6 SPAIN 190
11.3.6.1 Increasing focus on personalized medicine to propel market 190
TABLE 173 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 191
TABLE 174 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 175 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 176 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 177 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 178 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 193
TABLE 179 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 194
TABLE 180 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 181 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 182 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 195
TABLE 183 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 195
11.3.7 REST OF EUROPE 195
TABLE 184 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 196
TABLE 185 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 186 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 187 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 188 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 189 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 198
TABLE 190 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 199
TABLE 191 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 192 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 193 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 200
TABLE 194 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 200
11.4 ASIA PACIFIC 201
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT 202
TABLE 195 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 196 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 203
TABLE 197 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 198 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 199 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 201 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 205
TABLE 202 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 206
TABLE 203 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 204 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 207
TABLE 206 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 207
11.4.1 ASIA PACIFIC: RECESSION IMPACT 207
11.4.2 CHINA 208
11.4.2.1 Advancements in healthcare facilities to drive market 208
TABLE 207 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 208
TABLE 208 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 209
TABLE 209 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 210 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 211 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 212 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 213 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 211
TABLE 214 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 211
TABLE 215 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 216 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 217 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 212
TABLE 218 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 213
11.4.3 JAPAN 213
11.4.3.1 Research initiatives to support market growth 213
TABLE 219 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 214
TABLE 220 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 214
TABLE 221 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 222 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 223 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 224 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 225 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 216
TABLE 226 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 217
TABLE 227 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 228 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 229 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 218
TABLE 230 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 218
11.4.4 INDIA 218
11.4.4.1 Increased demand for early cancer diagnosis to drive market 218
TABLE 231 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 219
TABLE 232 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 220
TABLE 233 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 234 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 235 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 236 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 237 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 222
TABLE 238 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 222
TABLE 239 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 240 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 241 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 223
TABLE 242 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 224
11.4.5 REST OF ASIA PACIFIC 224
TABLE 243 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 225
TABLE 244 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 245 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 246 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 247 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 248 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 227
TABLE 249 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 227
TABLE 250 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 251 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 252 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 228
TABLE 253 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 229
11.5 LATIN AMERICA 229
TABLE 254 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 230
TABLE 255 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 230
TABLE 256 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 257 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 258 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 259 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 260 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 232
TABLE 261 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 233
TABLE 262 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 263 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 264 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 234
TABLE 265 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 234
11.5.1 LATIN AMERICA: RECESSION IMPACT 234
11.5.2 BRAZIL 235
11.5.2.1 Increasing incidence of cancer to drive market 235
TABLE 266 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 235
TABLE 267 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 268 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 269 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 270 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 271 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 237
TABLE 272 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 238
TABLE 273 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 274 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 275 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 239
TABLE 276 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 239
11.5.3 MEXICO 239
11.5.3.1 Growing medical tourism to fuel demand for cancer diagnostics 239
TABLE 277 MEXICO: NUMBER OF CANCER CASES, BY CANCER TYPE, 2022 240
TABLE 278 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 240
TABLE 279 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 280 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 281 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 282 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 283 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 242
TABLE 284 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 243
TABLE 285 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 286 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 287 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 244
TABLE 288 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 244
11.5.4 REST OF LATIN AMERICA 244
TABLE 289 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 245
TABLE 290 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 291 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 292 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 246
TABLE 293 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 294 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 247
TABLE 295 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 248
TABLE 296 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 297 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 298 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 249
TABLE 299 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 249
11.6 MIDDLE EAST & AFRICA 250
11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET 250
TABLE 300 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 250
TABLE 301 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 302 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 303 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 304 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 305 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 252
TABLE 306 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 253
TABLE 307 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 308 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 309 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 254
TABLE 310 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 254
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 254
11.7 GCC 255
11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH 255
TABLE 311 GCC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION) 255
TABLE 312 GCC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 313 GCC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 314 GCC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 315 GCC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 316 GCC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION) 257
TABLE 317 GCC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 258
TABLE 318 GCC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 319 GCC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 320 GCC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 259
TABLE 321 GCC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 259
11.7.2 GCC: RECESSION IMPACT 260
12 COMPETITIVE LANDSCAPE 261
12.1 OVERVIEW 261
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 261
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER BIOMARKERS MARKET 261
TABLE 322 CANCER BIOMARKERS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 261
12.3 REVENUE SHARE ANALYSIS 263
FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2019–2023 (USD MILLION) 263
12.4 MARKET SHARE ANALYSIS 264
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 264
TABLE 323 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION 264
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 265
12.5.1 STARS 265
12.5.2 EMERGING LEADERS 265
12.5.3 PERVASIVE PLAYERS 265
12.5.4 PARTICIPANTS 266
FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 266
12.5.5 COMPANY FOOTPRINT 267
12.5.5.1 Overall company footprint 267
FIGURE 39 CANCER BIOMARKERS MARKET: OVERALL COMPANY FOOTPRINT 267
12.5.5.2 Product footprint 267
TABLE 324 CANCER BIOMARKERS MARKET: PRODUCT FOOTPRINT 267
12.5.5.3 Profiling technology footprint 268
TABLE 325 CANCER BIOMARKERS MARKET: PROFILING TECHNOLOGY FOOTPRINT 268
12.5.5.4 Application footprint 268
TABLE 326 CANCER BIOMARKERS MARKET: APPLICATION FOOTPRINT 268
12.5.5.5 Regional footprint 268
TABLE 327 CANCER BIOMARKERS MARKET: REGIONAL FOOTPRINT 268
12.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES (2023) 269
12.6.1 PROGRESSIVE COMPANIES 269
12.6.2 RESPONSIVE COMPANIES 269
12.6.3 DYNAMIC COMPANIES 269
12.6.4 STARTING BLOCKS 269
FIGURE 40 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 270
12.6.5 COMPETITIVE BENCHMARKING 270
TABLE 328 CANCER BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 270
TABLE 329 CANCER BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 271
12.7 VALUATION AND FINANCIAL METRICS OF CANCER BIOMARKER VENDORS 271
FIGURE 41 EV/EBITDA OF KEY VENDORS 271
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 272
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 272
FIGURE 43 PRODUCT/BRAND COMPARATIVE ANALYSIS 272
12.8.1 F. HOFFMANN-LA ROCHE LTD. 273
12.8.2 AGILENT TECHNOLOGIES, INC. 273
12.8.3 QIAGEN 273
12.8.4 ABBOTT 273
12.9 COMPETITIVE SCENARIO 274
12.9.1 PRODUCT LAUNCHES & APPROVALS 274
TABLE 330 CANCER BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024 274
12.9.2 DEALS 275
TABLE 331 CANCER BIOMARKERS MARKET: DEALS, JANUARY 2021–MARCH 2024 275
13 COMPANY PROFILES 276
(Business overview, Products offered, Recent developments & MnM View)*
13.1 KEY PLAYERS 276
13.1.1 F. HOFFMANN-LA ROCHE LTD. 276
TABLE 332 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 276
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 277
TABLE 333 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED 278
TABLE 334 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS 280
TABLE 335 F. HOFFMANN-LA ROCHE LTD.: DEALS 281
13.1.2 THERMO FISHER SCIENTIFIC INC. 282
TABLE 336 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 282
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 283
TABLE 337 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 283
TABLE 338 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS 286
TABLE 339 THERMO FISHER SCIENTIFIC INC.: DEALS 287
13.1.3 QIAGEN 288
TABLE 340 QIAGEN: COMPANY OVERVIEW 288
FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2023) 289
TABLE 341 QIAGEN: PRODUCTS & SERVICES OFFERED 290
TABLE 342 QIAGEN: PRODUCT LAUNCHES & APPROVALS 291
TABLE 343 QIAGEN: DEALS 291
13.1.4 BIO-RAD LABORATORIES, INC. 293
TABLE 344 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 293
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 294
TABLE 345 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 294
13.1.5 ILLUMINA, INC. 296
TABLE 346 ILLUMINA, INC.: COMPANY OVERVIEW 296
FIGURE 48 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 297
TABLE 347 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 297
TABLE 348 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS 299
TABLE 349 ILLUMINA, INC.: DEALS 299
13.1.6 AGILENT TECHNOLOGIES, INC. 301
TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 301
FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 302
TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 302
TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS 304
TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS 305
13.1.7 ABBOTT LABORATORIES 306
TABLE 354 ABBOTT: COMPANY OVERVIEW 306
FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023) 307
TABLE 355 ABBOTT: PRODUCTS & SERVICES OFFERED 308
13.1.8 BIOMÉRIEUX 309
TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW 309
FIGURE 51 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) 310
TABLE 357 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED 310
13.1.9 MERCK KGAA 311
TABLE 358 MERCK KGAA: BUSINESS OVERVIEW 311
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023) 312
TABLE 359 MERCK KGAA: PRODUCTS & SERVICES OFFERED 313
TABLE 360 MERCK KGAA: DEALS 314
TABLE 361 MERCK KGAA: OTHER DEVELOPMENTS 314
13.1.10 BECTON, DICKINSON AND COMPANY 315
TABLE 362 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 315
FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 316
TABLE 363 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED 317
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 318
13.2.1 MYRIAD GENETICS, INC. 318
13.2.2 SYSMEX CORPORATION 319
13.2.3 HOLOGIC, INC. 320
13.2.4 QUEST DIAGNOSTICS 321
13.2.5 CENTOGENE N.V. 321
13.2.6 BIOGENEX 322
TABLE 364 BIOGENEX: COMPANY OVERVIEW 322
13.2.7 SIEMENS HEALTHINEERS 323
13.2.8 EXACT SCIENCES 324
13.2.9 R&D SYSTEMS, INC. 325
13.2.10 BIOVISION INC. 326
13.2.11 OLINK 327
13.2.12 ASURAGEN, INC. 327
13.2.13 MESO SCALE DIAGNOSTICS, LLC 328
13.2.14 INVIVOSCRIBE, INC. 329
13.2.15 INOVIQ LTD. 329
14 APPENDIX 330
14.1 DISCUSSION GUIDE 330
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 335
14.3 CUSTOMIZATION OPTIONS 337
14.4 RELATED REPORTS 337
14.5 AUTHOR DETAILS 338
